{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:34:10Z","timestamp":1768293250656,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 AI08764301-A1"],"award-info":[{"award-number":["R01 AI08764301-A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-13-00084"],"award-info":[{"award-number":["AID-OAA-A-13-00084"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sealy Center for Vaccine Development at the University of Texas Medical Branch at Galveston"},{"name":"James W. McLaughlin Postdoctoral Fellowship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.036","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T09:45:56Z","timestamp":1508492756000},"page":"6634-6642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"PB","title":["Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain"],"prefix":"10.1016","volume":"35","author":[{"given":"Hoai J.","family":"Ly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandadeva","family":"Lokugamage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry L.","family":"Juelich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.036_b0005","series-title":"Rift Valley fever","first-page":"1037","author":"Swanepoel","year":"2004"},{"key":"10.1016\/j.vaccine.2017.10.036_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2017.10.036_b0020","first-page":"12634","article-title":"Challenges and practices in building and implementing biosafety and biosecurity programs to enable basic and translational research with select agents","author":"Jonsson","year":"2013","journal-title":"J Bioterror Biodef"},{"key":"10.1016\/j.vaccine.2017.10.036_b0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep cattle and man from east Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J Path Bact"},{"key":"10.1016\/j.vaccine.2017.10.036_b0030","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0035","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1128\/JVI.00335-11","article-title":"Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting from virus introductions from the East African mainland rather than enzootic maintenance","volume":"85","author":"Carroll","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0040","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.10.036_b0045","doi-asserted-by":"crossref","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","article-title":"Rift valley fever vaccines","volume":"27","author":"Ikegami","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.036_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0055","doi-asserted-by":"crossref","first-page":"7346294","DOI":"10.1155\/2016\/7346294","article-title":"Safety and efficacy profile of commercial veterinary vaccines against Rift Valley fever: a review study","volume":"2016","author":"Alhaj","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0060","first-page":"261","article-title":"The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO\/FAO meeting","volume":"61","author":"WHO","year":"1983","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.10.036_b0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"Pt 10","key":"10.1016\/j.vaccine.2017.10.036_b0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0075","unstructured":"Hills RE. Issuance of a conditional license for Rift Valley fever vaccine, modified live virus. Notice no. 13-12. Ames, IA: Center for Veterinary Biologics; 2013."},{"key":"10.1016\/j.vaccine.2017.10.036_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.036_b0085","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0090","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0095","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0100","first-page":"787","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J MedVirol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fcimb.2012.00131","article-title":"Novel approaches to develop Rift Valley fever vaccines","volume":"2","author":"Indran","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virusres.2015.05.012","article-title":"Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates","volume":"216","author":"Terasaki","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0115","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.10.036_b0120","doi-asserted-by":"crossref","first-page":"27719","DOI":"10.1038\/srep27719","article-title":"A recombinant Rift Valley fever virus glycoprotein subunit vaccine confers full protection against Rift Valley fever challenge in sheep","volume":"6","author":"Faburay","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.10.036_b0125","doi-asserted-by":"crossref","first-page":"e0185194","DOI":"10.1371\/journal.pone.0185194","article-title":"Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain","volume":"12","author":"Ly","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.10.036_b0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0135","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene","volume":"80","author":"Ikegami","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0140","first-page":"e3400","article-title":"Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy","author":"Kalveram","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2017.10.036_b0145","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.10.036_b0150","unstructured":"GenScript Rare Codon Analysis Tool [database on the Internet]. Available from: <https:\/\/www.genscript.com\/tools\/rare-codon-analysis>."},{"key":"10.1016\/j.vaccine.2017.10.036_b0155","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1128\/JVI.00778-12","article-title":"The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine","volume":"86","author":"Lihoradova","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0160","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1073\/pnas.86.10.3699","article-title":"Nonrandom utilization of codon pairs in Escherichia coli","volume":"86","author":"Gutman","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.10.036_b0165","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/gb-2005-6-3-r28","article-title":"Comparative context analysis of codon pairs on an ORFeome scale","volume":"6","author":"Moura","year":"2005","journal-title":"Genome Biol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1745-6150-3-38","article-title":"CAIcal: a combined set of tools to assess codon usage adaptation","volume":"3","author":"Puigbo","year":"2008","journal-title":"Biol Direct"},{"key":"10.1016\/j.vaccine.2017.10.036_b0175","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0180","doi-asserted-by":"crossref","first-page":"e2181","DOI":"10.1371\/journal.pntd.0002181","article-title":"Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever sicilian virus","volume":"7","author":"Lihoradova","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.10.036_b0185","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1128\/JVI.02241-15","article-title":"The L-, M- and S-segments of Rift Valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype","volume":"90","author":"Nishiyama","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.virol.2008.05.033","article-title":"RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses","volume":"378","author":"Billecocq","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.10.036_b0195","first-page":"1","article-title":"Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR","author":"Nishiyama","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2017.10.036_b0200","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.036_b0210","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.036_b0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2007.01.046","article-title":"Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease","volume":"362","author":"Bird","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.10.036_b0220","doi-asserted-by":"crossref","first-page":"9957","DOI":"10.1128\/JVI.00508-09","article-title":"Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons","volume":"83","author":"Burns","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0225","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1093\/nar\/gku075","article-title":"The influence of CpG and UpA dinucleotide frequencies on RNA virus replication and characterization of the innate cellular pathways underlying virus attenuation and enhanced replication","volume":"42","author":"Atkinson","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2017.10.036_b0230","doi-asserted-by":"crossref","first-page":"e04531","DOI":"10.7554\/eLife.04531","article-title":"RNA virus attenuation by codon pair deoptimisation is an artefact of increases in CpG\/UpA dinucleotide frequencies","volume":"3","author":"Tulloch","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.vaccine.2017.10.036_b0235","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/fvl.15.31","article-title":"Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines","volume":"10","author":"Baker","year":"2015","journal-title":"Fut Virol"},{"key":"10.1016\/j.vaccine.2017.10.036_b0240","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00237-15","article-title":"Recoding of the vesicular stomatitis virus L gene by computer-aided design provides a live, attenuated vaccine candidate","volume":"6","author":"Wang","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2017.10.036_b0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/hv.4.1.4747","article-title":"Evidence based route of administration of vaccines","volume":"4","author":"Cook","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.10.036_b0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.036_b0255","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turell","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.10.036_b0260","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the efficacy, potential for vector transmission, and duration of immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate, in sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:18Z","timestamp":1759400598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":52,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314445"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}